Low bone density is most commonly associated with osteoporosis, an age-related disorder that consists of decreased bone mass and increased susceptibility to fractures. Osteoporosis is most commonly seen in postmenopausal women, with about 1.2 million fractures per year attributed to the condition, and of these fractures, about one-third are compressed fractures of the spine. Lately, doctors are finding the trend of those diagnosed with low bone density is changing: an increasingly large amount of men, younger women and even children are being diagnosed with decreased bone mass. Many of those diagnosed with the condition were not fully aware of their susceptibility.
To detect osteoporosis accurately, Centrelake Imaging & Oncology uses an enhanced form of x-ray technology called dual-energy x-ray absorptiometry (DEXA). DEXA bone densitometry is today's established standard for measuring bone mineral density (BMD). DEXA is a quick, painless procedure for measuring bone loss. Measurement of the lower spine and hips are most often performed. The DEXA test can also assess your risk for developing fractures. If the bone density is found to be low, the patient and referring physician can work together on a treatment plan to help prevent fractures before they occur. DEXA is also effective in tracking the effects of treatment from osteoporosis or for other conditions that can cause bone loss.
Indications for bone mineral density (BMD) testing:
- Women age 65 and older
- Postmenopausal women under age 65 with risk factors.
- Men aged 70 and older
- Adults with fragility fracture
- Adults with a disease or condition associated with low bone mass or bone loss.
- Adults taking medications associated with low bone mass or bone loss.
- Anyone being considered for pharmacologic therapy for bone loss.
- Anyone being treated for bone loss, to monitor treatment effect.
- Anyone not receiving therapy in whom evidence of bone loss would lead to treatment.